RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
PCI Biotech Holding A Stock

PCI Biotech Holding A P/E 2024

PCI Biotech Holding A P/E

-0.89

Ticker

PCIB.OL

ISIN

NO0010405640

WKN

A0Q2FS

As of Nov 22, 2024, PCI Biotech Holding A's P/E ratio was -0.89, a -72.7% change from the -3.26 P/E ratio recorded in the previous year.

The PCI Biotech Holding A P/E history

PCI Biotech Holding A Aktienanalyse

What does PCI Biotech Holding A do?

PCI Biotech Holding ASA is a biopharmaceutical company based in Norway that focuses on the clinical development of drugs based on the so-called "Photochemical Internalization" (PCI) technology. The company was founded in 2000 as a spin-off from the Norwegian Cancer Society. The PCI technology, which is based on the use of light and chemicals to transport drugs into cells, was developed by Norwegian researchers in the 1990s. Since then, PCI Biotech has been working in collaboration with various research institutions and pharmaceutical companies to optimize this technology and advance its application in medicine. PCI Biotech's business model is based on providing its PCI technology and expertise to partners in research and industry. At the same time, the company also conducts its own clinical research on drugs based on the PCI technology. The goal is to develop drugs that are effective in various forms of cancer and other serious diseases. PCI Biotech is divided into two main divisions: the project department, which works on the development of its own drugs, and the service department, which licenses its PCI technology to third parties. One significant product of the project department is the drug "Amphinex," which is used in the treatment of pancreatic cancer. Amphinex is administered to patients in combination with chemotherapy to enhance the effectiveness of the chemotherapy. Amphinex activates the PCI technology in cancer cells, thereby facilitating the penetration of the chemotherapeutic agent into the cells. Other projects in the company's pipeline include drugs for the treatment of prostate cancer and skin cancer, as well as targeted destruction of tumor cells in the brain. The service department offers various solutions for the academic and industrial sectors. The PCI technology can be used in the development of drugs for the treatment of other diseases, such as viral infections or inflammatory diseases. Furthermore, the PCI technology can also be utilized in imaging or diagnostics. Overall, PCI Biotech is a company specialized in the development of innovative drugs. By using the PCI technology, drugs can be delivered more specifically and effectively into cells, opening up new possibilities in cancer treatment and other areas of medicine. PCI Biotech has become a significant player in clinical research in recent years and works closely with other research institutions and pharmaceutical companies to optimize their technology and explore new application areas. PCI Biotech Holding A ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering PCI Biotech Holding A's P/E Ratio

The Price to Earnings (P/E) Ratio of PCI Biotech Holding A is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing PCI Biotech Holding A's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of PCI Biotech Holding A is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in PCI Biotech Holding A’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about PCI Biotech Holding A stock

What is the price-to-earnings ratio of PCI Biotech Holding A?

The price-earnings ratio of PCI Biotech Holding A is currently -0.89.

How has the price-earnings ratio of PCI Biotech Holding A changed compared to last year?

The price-to-earnings ratio of PCI Biotech Holding A has increased by -72.7% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of PCI Biotech Holding A high compared to other companies?

Yes, the price-to-earnings ratio of PCI Biotech Holding A is high compared to other companies.

How does an increase in the price-earnings ratio of PCI Biotech Holding A affect the company?

An increase in the price-earnings ratio of PCI Biotech Holding A would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of PCI Biotech Holding A affect the company?

A decrease in the price-earnings ratio of PCI Biotech Holding A would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of PCI Biotech Holding A?

Some factors that influence the price-earnings ratio of PCI Biotech Holding A are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does PCI Biotech Holding A pay?

Over the past 12 months, PCI Biotech Holding A paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, PCI Biotech Holding A is expected to pay a dividend of 0 NOK.

What is the dividend yield of PCI Biotech Holding A?

The current dividend yield of PCI Biotech Holding A is .

When does PCI Biotech Holding A pay dividends?

PCI Biotech Holding A pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of PCI Biotech Holding A?

PCI Biotech Holding A paid dividends every year for the past 0 years.

What is the dividend of PCI Biotech Holding A?

For the upcoming 12 months, dividends amounting to 0 NOK are expected. This corresponds to a dividend yield of 0 %.

In which sector is PCI Biotech Holding A located?

PCI Biotech Holding A is assigned to the 'Health' sector.

Wann musste ich die Aktien von PCI Biotech Holding A kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of PCI Biotech Holding A from 11/22/2024 amounting to 0 NOK, you needed to have the stock in your portfolio before the ex-date on 11/22/2024.

When did PCI Biotech Holding A pay the last dividend?

The last dividend was paid out on 11/22/2024.

What was the dividend of PCI Biotech Holding A in the year 2023?

In the year 2023, PCI Biotech Holding A distributed 0 NOK as dividends.

In which currency does PCI Biotech Holding A pay out the dividend?

The dividends of PCI Biotech Holding A are distributed in NOK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von PCI Biotech Holding A

Our stock analysis for PCI Biotech Holding A Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PCI Biotech Holding A Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.